Agilon Health, Inc. (AGL) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Agilon Health operates a Medicare-centric, globally capitated line of business, partnering with physician groups to manage care for Medicare Advantage members. As of June 30, 2025, the Company provided care to approximately 497,500 Medicare Advantage members, a 3% decrease from the prior year. The Company also participates in CMS ACO Models with approximately 116,000 attributed beneficiaries.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenues | $1,394,982 | $1,482,758 | $2,927,764 | $3,087,112 |
| Medical Services Expense | $1,445,245 | $1,374,060 | $2,847,112 | $2,817,902 |
| Gross Profit (Loss) | $(52,427) | $32,175 | $(1,705) | $107,263 |
| Net Income (Loss) | $(104,370) | $(30,662) | $(92,258) | $(36,696) |
| Adjusted EBITDA | $(83,333) | $(2,830) | $(62,766) | $26,224 |
| Cash & Equivalents | $171,416 | $188,231 | $171,416 | $116,336 |
| Marketable Securities | $155,585 | $211,737 | $155,585 | $211,737 |
| Debt Outstanding | $34,945 | $34,904 | $34,945 | $34,904 |
Note: Debt consists of a $35.0 million Secured Term Loan. The Revolving Credit Facility has $19.4 million availability after $80.6 million in outstanding letters of credit.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 6% in Q2 and 5% YTD compared to 2024. This was driven by a 3% decline in average membership due to partnership exits in 2024, lower risk adjustment revenue, and unfavorable prior period development.
- Margin Compression: The Company reported a negative medical margin of $53.2 million in Q2 2025, compared to a positive $105.5 million in Q2 2024. Medical services expense increased 5% in Q2 due to a 7% increase in per-member costs, which outpaced the 2% decline in membership.
- Expense Reductions: Other medical expenses dropped significantly (97% in Q2) due to reduced partner physician incentive expenses resulting from losses in certain geographies and partnership exits. General and administrative expenses decreased 19% in Q2.
- Discontinued Operations: The YTD 2025 results include a $14.0 million gain from discontinued operations (Hawaii exit), compared to a $9.3 million loss in the prior year.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes existing cash, marketable securities, and borrowing capacity are sufficient for the next 12 months. However, the Company expects to continue incurring operating losses and generating negative cash flows from operations.
- Operational Initiatives: The Company implemented a new "payor data pipeline" in Q1 2025 to enhance visibility into member risk profiles. Onboarding of payors to this model is ongoing.
- Legal Proceedings: The Company is defending against a consolidated securities class action lawsuit and derivative matters alleging fraud related to financial guidance and data management. Motions to dismiss are pending. The Company cannot estimate potential liability at this stage.
- Tax Legislation: The "One Big Beautiful Bill Act" signed on July 4, 2025, contains tax reform provisions. The Company is evaluating the impact on its effective tax rate and financial position.
- Debt Covenants: The Company is in compliance with all covenants under its Credit Facility, which matures in February 2026.
Key Investor Verification Points
- Medical Cost Trends: Verify the sustainability of the 7% increase in per-member medical costs and the trajectory of medical margin recovery.
- Membership Stability: Assess the impact of 2024 partnership exits on future growth and the success of new geography onboarding.
- Risk Adjustment Accuracy: Review the impact of unfavorable prior period development on risk adjustment revenue and the efficacy of the new data pipeline.
- Legal Exposure: Monitor the status of the consolidated securities litigation and potential financial impact of any settlements or judgments.
- Cash Burn Rate: Evaluate the runway provided by current liquidity ($327 million in cash/securities) against the continued negative operating cash flow.